No black box warning on record for Tazverik

As of the latest FDA labeling reviewed, Tazverik (TAZEMETOSTAT) does not carry a black box warning. Standard warnings and precautions still apply — see the full Tazverik medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Secondary Malignancies : TAZVERIK increases the risk of developing secondary malignancies, including T-cell lymphoblastic lymphoma, myelodysplastic syndrome, acute myeloid leukemia, and B-cell acute lymphoblastic leukemia. Monitor patients long-term for the development of secondary malignancies. ( 5.1 ) Embryo-Fetal Toxicity : Can cause fetal harm. Advise patients of pot

No black box warning on record for Tazverik

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Secondary Malignancies : TAZVERIK increases the risk of developing secondary malignancies, including T-cell lymphoblastic lymphoma, myelodysplastic syndrome, acute myeloid leukemia, and B-cell acute lymphoblastic leukemia. Monitor patients long-term for the development of secondary malignancies. ( 5.1 ) Embryo-Fetal Toxicity : Can cause fetal harm. Advise patients of pot

Tazverik Black Box Warning

No black box warning on record for Tazverik

Other warnings & precautions

Tazverik Black Box Warning

No black box warning on record for Tazverik

Other warnings & precautions